Virtual Library

Start Your Search

Sawsan Rashdan



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-37 - A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC (ID 14249)

      16:45 - 18:00  |  Author(s): Sawsan Rashdan

      • Abstract

      Background

      AXL is a receptor tyrosine kinase expressed on tumor as well as innate immune cells. AXL regulates multiple cellular processes including tumour cell survival, therapy resistance as well as immunosuppression in the tumour microenvironment. AXL overexpression is an independent negative prognostic factor in NSCLC. Bemcentinib (BGB324) is a phase 2, highly selective, orally bioavailable small molecule AXL kinase inhibitor shown to increase efficacy of chemo-, targeted- and immuno-therapies in NSCLC in vivo models. Preclinically, the combination of bemcentinib with docetaxel was shown to be additive in in vivo models of NSCLC.

      In pts with advanced, pre-treated NSCLC, bemcentinib monotherapy led to disease stabilization in 2 out of 8 pts including evidence of tumor reduction. Clinical benefit including partial responses and disease stabilization in excess of 2 years has been observed in a subset of EGFR therapy resistant previously treated NSCLC pts when treated with bemcentinib in combination with erlotinib. In a study combining bemcentinib with pembrolizumab, objective responses have been reported in pts with previously treated NSCLC.

      The BGBIL005 trial (NCT02922777) is an open label, investigator-initiated dose escalation and expansion trial designed to assess the safety, tolerability, preliminary efficacy and biomarkers of bemcentinib in combination with docetaxel in previously treated NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Dose escalation of daily bemcentinib in combination with 60 or 75 mg/m2 q3wks followed a standard 3+3 design in pts with at least one line of prior Pt-based doublet therapy and appropriate targeted therapy if indicated. Tumor responses were assessed per investigator using RECIST v1.1. Plasma protein biomarker levels were measured using the DiscoveryMap v3.3 panel (Myriad RBM) in pts pre-dose and at C2D1.

      4c3880bb027f159e801041b1021e88e8 Result

      As of 30th April, 12 patients have been enrolled. The starting dose of 75 mg/m2 docetaxel and 100 mg daily of bemcentinib led to 2 hematological DLTs, thus recruitment is currently ongoing at 60 mg/m2 docetaxel and 100 mg bemcentinib. Confirmed objective responses have been reported at both dose levels. All pts benefitting had received prior immune checkpoint inhibitor (CPI) therapy and some had been refractory to this treatment. Candidate predictive and pharmacodynamic biomarkers have been identified.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The combination of bemcentinib and docetaxel is active in pts with advanced NSCLC who progressed on chemotherapy, targeted therapy (where applicable) as well as CPIs.

      6f8b794f3246b0c1e1780bb4d4d5dc53